Rationaler for behandling med januskinase 1/2-hæmning af svært syge patienter med COVID-19-pneumoni

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Severely afflicted patients with the COVID-19 may become in need of mechanical ventilation. The cause of acute respiratory failure is a massive hyperinflammation in the lungs, and treatment with glucocorticoids is not recommended by the WHO. A rare haematological disease, the virus-associated haemophagocytic lymphohistiocytosis syndrome (HLS), is associated with high mortality and a similar hyperinflammation syndrome. Janus kinase (JAK) 1/2 inhibitor treatment is highly efficacious in HLS. In this review, we discuss the rationales and perspectives for using JAK1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia.

Bidragets oversatte titelRationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia
TidsskriftUgeskrift for Laeger
Udgave nummer25
Antal sider9
StatusUdgivet - 2020


  • Betacoronavirus, COVID-19, Coronavirus Infections/drug therapy, Humans, Janus Kinase Inhibitors/therapeutic use, Lymphohistiocytosis, Hemophagocytic/drug therapy, Pandemics, Pneumonia, Viral/drug therapy, SARS-CoV-2

ID: 269690725